Sandra Garcia1, Jessica M Saltarski2, Jingsheng Yan3, Xian-Jin Xie4, David E Gerber5. 1. School of Medicine, University of Texas Southwestern Medical Center, Dallas, TX. 2. Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX. 3. Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX. 4. Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX. 5. Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: david.gerber@utsouthwestern.edu.
Abstract
BACKGROUND: Increasingly, analysis of tumor tissue samples for predictive and pharmacodynamic biomarkers is incorporated into lung cancer clinical trials. We determined the time and effort required for tissue acquisition and submission. PATIENTS AND METHODS: We analyzed data from patients enrolled from 2009 to 2016 at UT Southwestern onto lung cancer trials with mandatory or optional submission of tumor tissue. We collected dates of treatment-related events and staff communications; nature of tissue requirement and biomarker analysis; and location of archival tissue. Associations between case characteristics, clinical intervals, and number of staff communications were analyzed by Fisher's exact test, Wilcoxon 2-sample test, and Kruskal-Wallis test. RESULTS: We identified 129 patients enrolled onto 19 clinical trials, of whom 108 (84%) ultimately received study therapy. For cases in which tissue submission was required if available or optional, 16% and 0%, respectively, had tissue sent. The median interval between consent and treatment was 28 (interquartile range, 11-43) days if tissue was requested and 7 (interquartile range, 6-13) days if tissue was not requested (P < .001). Among cases with requested tissue, the median number of related research staff communications was 3 (range, 0-10). Over time, the number of staff communications increased (P < .001). Location of archival tissue was not associated with number of staff communications or treatment intervals. CONCLUSION: Lung cancer clinical trial requirements for tissue acquisition and submission affect the time to treatment initiation and require increasing staff effort. Improved systems to expedite these processes, as well as use of blood- or imaging-based biomarkers, may help address these issues.
BACKGROUND: Increasingly, analysis of tumor tissue samples for predictive and pharmacodynamic biomarkers is incorporated into lung cancer clinical trials. We determined the time and effort required for tissue acquisition and submission. PATIENTS AND METHODS: We analyzed data from patients enrolled from 2009 to 2016 at UT Southwestern onto lung cancer trials with mandatory or optional submission of tumor tissue. We collected dates of treatment-related events and staff communications; nature of tissue requirement and biomarker analysis; and location of archival tissue. Associations between case characteristics, clinical intervals, and number of staff communications were analyzed by Fisher's exact test, Wilcoxon 2-sample test, and Kruskal-Wallis test. RESULTS: We identified 129 patients enrolled onto 19 clinical trials, of whom 108 (84%) ultimately received study therapy. For cases in which tissue submission was required if available or optional, 16% and 0%, respectively, had tissue sent. The median interval between consent and treatment was 28 (interquartile range, 11-43) days if tissue was requested and 7 (interquartile range, 6-13) days if tissue was not requested (P < .001). Among cases with requested tissue, the median number of related research staff communications was 3 (range, 0-10). Over time, the number of staff communications increased (P < .001). Location of archival tissue was not associated with number of staff communications or treatment intervals. CONCLUSION:Lung cancer clinical trial requirements for tissue acquisition and submission affect the time to treatment initiation and require increasing staff effort. Improved systems to expedite these processes, as well as use of blood- or imaging-based biomarkers, may help address these issues.
Authors: Mollie W Howerton; M Chris Gibbons; Charles R Baffi; Tiffany L Gary; Gabriel Y Lai; Shari Bolen; Jon Tilburt; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass; Jean G Ford Journal: Cancer Date: 2007-02-01 Impact factor: 6.860
Authors: C Lim; M S Tsao; L W Le; F A Shepherd; R Feld; R L Burkes; G Liu; S Kamel-Reid; D Hwang; J Tanguay; G da Cunha Santos; N B Leighl Journal: Ann Oncol Date: 2015-04-28 Impact factor: 32.976
Authors: P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: David E Gerber; Drew W Rasco; Celette Sugg Skinner; Jonathan E Dowell; Jingsheng Yan; Jennifer R Sayne; Yang Xie Journal: J Oncol Pract Date: 2011-12-06 Impact factor: 3.840
Authors: Sandra Garcia; Ajit Bisen; Jingsheng Yan; Xian-Jin Xie; Suresh Ramalingam; Joan H Schiller; David H Johnson; David E Gerber Journal: J Thorac Oncol Date: 2017-08-09 Impact factor: 15.609
Authors: Marshall L Spiegel; Jonathan W Goldman; Brian R Wolf; Danielle J Nameth; Tristan R Grogan; Aaron E Lisberg; Deborah J L Wong; Blanca A Ledezma; Melody A Mendenhall; Scott J Genshaft; Antonio J Gutierrez; Fereidoun Abtin; W Dean Wallace; Carlos R Adame; Jordan R McKenzie; Phillip A Abarca; Alice J Li; Jennifer L Strunck; Sina Famenini; James M Carroll; D Andrew Tucker; Lauren M Sauer; Nima M Moghadam; David A Elashoff; Christina D Abaya; Meghan B Brennan; Edward B Garon Journal: Cancer Date: 2017-11-10 Impact factor: 6.860
Authors: David E Gerber; Mark A Socinski; Joel W Neal; Heather A Wakelee; Keisuke Shirai; Lecia V Sequist; Rachel P Rosovsky; Rogerio C Lilenbaum; Bruno R Bastos; Chao Huang; Melissa L Johnson; Paul J Hesketh; Deepa S Subramaniam; Martin F Dietrich; Feng Chai; Yunxia Wang; Julia Kazakin; Brian Schwartz; Joan H Schiller; Julie R Brahmer; Ronan J Kelly Journal: Lung Cancer Date: 2018-02-03 Impact factor: 5.705